Cipla Limited has formalized its leadership transition through a Board meeting held on 30th March, 2026, following the successful completion of its postal ballot process where shareholders approved all four proposed resolutions with strong majorities. The pharmaceutical company announced the results on 26th March, 2026, after the e-voting process concluded on 25th March, 2026.

Leadership Appointments Approved Through Postal Ballot

Shareholders demonstrated strong support for the company's leadership changes, approving the appointment of Mr Achin Gupta (DIN: 09491674) in multiple capacities. The voting results showed overwhelming approval across all shareholder categories.

Senior Management Personnel Categorization

Following Mr Achin Gupta taking charge as Managing Director and Global Chief Executive Officer, the Board of Directors formally categorized two key officials as Senior Management Personnel effective 1st April, 2026. Both officials report directly to the new MD and CEO.

Mr Saurabh Gambhir brings extensive experience from leadership roles at Emcure Pharmaceuticals, Intas Pharmaceuticals, and IMS Health (now IQVIA). He holds an MBA from IIM Ahmedabad and is responsible for strategic planning, inorganic growth opportunities, and digital transformation programs. At Cipla, he leads strategic planning, inorganic growth opportunities, and digital transformation programs, contributing to strengthening the company's competitive positioning.

Mr Satyavan Manikani joined Cipla in February 2022 and has previously held leadership positions at USV Limited, Gufic Biosciences Ltd, Alkem Labs, and Ranbaxy Labs. He is a pharmacy graduate with an MBA in Marketing from the Institute of Technology & Management, Mumbai, and leads portfolio initiatives globally.

Director Resignation Formalized

Upon completion of his term as Managing Director and Global Chief Executive Officer on 31st March, 2026, Mr Umang Vohra (DIN: 02296740) has resigned as Director of the company effective 1st April, 2026. In his resignation letter dated 30th March, 2026, Vohra expressed gratitude for his ten-year tenure at Cipla and acknowledged the support of Chairman Dr Y K Hamied and the Board.

Voting Participation and Regulatory Compliance

The postal ballot process witnessed significant shareholder participation, with 650905507 votes cast representing 80.58% of the total outstanding shares of 807780677. The e-voting facility was provided by National Securities Depository Limited (NSDL).

The postal ballot process was conducted in compliance with Section 108 and Section 110 of the Companies Act, 2013, along with relevant rules and SEBI Listing Regulations. The leadership changes have been disclosed under Regulation 30 of SEBI Listing Regulations, with detailed annexures providing comprehensive information as per SEBI circular requirements. The voting process was overseen by Mr Avinash Bagul, Partner at M/s BNP & Associates, ensuring full regulatory compliance.

Cipla Limited has announced the opening of a special window for the lodgement of transfer and dematerialisation of physical shares, following a directive from the Securities and Exchange Board of India (SEBI). This initiative provides eligible shareholders with an opportunity to convert their physical share certificates to electronic form and complete pending transfer processes.

SEBI Directive and Timeline

The pharmaceutical company issued the notice pursuant to SEBI Circular No. HO/3R/11/2026-MIRSD-PODI/37/50/2026 dated January 30, 2026. The special window will remain operational until February 4, 2027, giving shareholders nearly a year to complete their transfer and dematerialisation requirements.

Eligibility Criteria

Cipla has provided a detailed matrix outlining the eligibility conditions for shareholders to utilise this special window:

Exclusions and Restrictions

The company has specified that certain cases will not be considered under this special window:

• Cases involving disputes between transferor and transferee
• Shares which have been transferred to Investor Education and Protection Fund (IEPF)

Lock-in Period and Conditions

Shares lodged for transfer pursuant to this circular will be issued exclusively in dematerialised form and will be subject to a lock-in period of one year from the date of registration of transfer. During this lock-in period, such shares cannot be transferred or pledged.

Process and Contact Information

Eligible shareholders wishing to avail this opportunity must submit requisite documents to KFIN Technologies Limited, the company's Registrar and Share Transfer Agent. The documents should be sent to their Hyderabad office located at Selenium Tower B, Plot No. 31 & 32, Gachibowli, Nanakramguda, Serilingampally, Hyderabad, Telangana - 500 032.

For queries, shareholders can raise service requests at sivward@cskinfotech.com or cossecretary@cipla.com . The company has encouraged shareholders to take advantage of this special window introduced in their interest.